AtriCure (NASDAQ:ATRC) posted first-quarter results today that beat the consensus forecast on Wall Street.
The Mason, Ohio-based company reported losses of -$16.9 million, or -38¢ per share, on sales of $59.3 million for the three months ended March 31, for a sales growth of 11.37% compared with Q1 2020.
Adjusted to exclude one-time items, earnings per share were -32¢, 4¢ ahead of The Street, where analysts were looking for sales of $56.1 million.
“Our growth in the first quarter is a testament of our team’s strong execution and unwavering dedication despite continued COVID headwinds,” president and CEO Michael Carrel said in a news release. “As we navigate toward a return to normalcy, I am confident that we are extremely well-positioned for the future with our pathway of growth catalysts and the realization of these opportunities underway, beginning with Converge.”
AtriCure said it projects full-year revenue to be in the range of $252 million to $256 million. As with its previous guidance, the company said that the uncertainties surrounding the COVID-19 pandemic could impact the projection.
Shares in ATRC were down -1.65% to $64.91 apiece at market close yesterday.